Company intelligence / Profile preview
SolaranRx
Albuquerque, New Mexico, United Statessolaranrx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SolaranRx developed a proprietary peptide-based theranostic platform targeting the melanocortin 1 receptor, over-expressed in ~80% of metastatic melanoma. Their lead compound, SRX‑1177, showed proof-of-concept in mouse models and was selected as a top oncology project to watch. The company entered into a CRADA with the National Cancer Institute for further preclinical evaluation but is now out of business.
- Therapeutic areas
- Oncology
- Modalities
- PeptidesRadiopharmaceuticalCompanion imaging agent (diagnostic peptide)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
National Cancer Institute/NIH Cooperative Research and Development Agreement for preclinical studies on metastatic melanoma theranostics
Beyond the preview
Go deeper on SolaranRx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SolaranRx.